Learn about the latest promising breakthroughs in immunotherapy, the challenges facing their widespread use, and what your cancer team needs to know about the future of cancer treatment.
Find the CANCER BUZZ podcast on Apple Podcasts, Spotify, or wherever you get your podcasts!
The redirection of T cells against tumors holds significant promise for the treatment of cancer. Two main approaches for T-cell redirection involve their genetic modification with chimeric antigen receptors (CAR) or the use of bispecific antibodies that can bind to two different antigens simultaneously.
On this episode of CANCER BUZZ, learn about these promising breakthroughs, the challenges facing their widespread use, and what your cancer team needs to know about the future of cancer treatment.
Guest: Firas El Chaer, MD, Assistant Professor of Medicine, Department of Hematology and Oncology, University of Virginia, Emily Couric Clinical Cancer Center
Related Content:
The views and opinions expressed herein are those of the author(s)/faculty member(s) and do not reflect the official policy or position of their employer(s) or the Association of Cancer Care Centers.
July 8, 2026
June 30, 2026
At the 2026 ASCO Annual Meeting, the Louisiana Oncology Society received the ASCO Jeffrey C Ward Affiliate Advocacy Award for advancing critical advocacy priorities that have translated into meaningful legislative victories. The Iowa Oncology Society and Washington State Medical Oncology Society were also recognized for their advocacy efforts in 2025 at the meeting, receiving second place awards.
